Biosimilars in global markets
Emerging markets may be key to long-term growth
Analysts expect the worldwide biosimilars market to reach approximately $35 billion by 2020.ͥ While developed markets will remain important for biosimilars manufacturers, Deloitte analysis indicates that long-term growth may be fueled by emerging markets.
The challenge of compliance
Moving from cost to value
The life sciences industry faces unprecedented challenges amid increasing regulatory scrutiny. This latest Deloitte report explores the enterprise-wide compliance functions of major life science companies – identifying the big trends and opportunities to enable a move from cost to value.
High-value health care
Innovative approaches to global challenges
What are pioneering health care providers, health plans, and life science companies doing to anticipate patient needs, reduce costs, and improve overall health outcomes in the US and globally? Learn more in this new Deloitte Center for Health Solutions research.